AstraZeneca

PULMICORT RESPULES offers flexible dosing

For your pediatric patients, one size may not always fit all. PULMICORT RESPULES can be administered once- or twice-daily in varying doses to help meet your patients’ needs. Flexible once- or twice-daily dosing allows for therapy adjustments.

Dosing Chart

View larger image

  • Clinical trials have shown that PULMICORT RESPULES improves asthma symptoms scores when dosed once or twice daily. However, when all measures were considered together, the evidence was stronger for twice-daily dosing1,2,3
  • Dosing for PULMICORT RESPULES is not based on weight but on previous therapy
  • Once the desired clinical effect is achieved, consideration should be given to titrating to the lowest effective dose
  • Improvement in asthma control can occur within 2 to 8 days of initiation of treatment, although maximum benefit may not be achieved for 4 to 6 weeks
  • In symptomatic patients not responding to nonsteroid asthma therapy, a starting dose of 0.25 mg once daily of PULMICORT RESPULES may be considered
  • Particular care is needed for patients who are transferred from systemically active corticosteroids to less systemically available corticosteroids, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids (see WARNINGS in full Prescribing Information)
Next
Learn how PULMICORT RESPULES is delivered right to the lungs

Indication and Important Safety Information

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

Common adverse events reported in clinical trials, regardless of relationship to treatment, included respiratory infection, rhinitis, coughing, otitis media, viral infection, gastroenteritis, ear infection, oral thrush/candidiasis, and epistaxis.

Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

PULMICORT RESPULES, like other inhaled corticosteroids, may impact the hypothalamic-pituitary-adrenal axis, especially in susceptible individuals, in young children, and in patients given high doses for prolonged periods.

Particular care is needed for patients who are transferred from systemically active corticosteroids to less systemically available corticosteroids, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids (see WARNINGS in full Prescribing Information).

Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

[Please see accompanying full Prescribing Information.]

References

  1. Kemp JP, Skoner DP, Szefler SJ, et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol. 1999;83:231-239.
  2. Shapiro G, Mendelson L, Kraemer MJ, et al. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol. 1998:102:789-796.
  3. Baker JW, Mellon M, Wald J, et al. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics. 1999;103:414-421.